Cytogen, Inc. (KOSDAQ: 217330)

Market Cap	126.42B
Revenue (ttm)	6.19B
Net Income (ttm)	-16.00B
Shares Out	23.07M
EPS (ttm)	-741.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,842
Open	5,330.00
Previous Close	5,400.00
Day's Range	5,050.00 - 5,720.00
52-Week Range	3,780.00 - 16,640.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About Cytogen

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is head...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2010
• Employees: 51
• Stock Exchange: KOSDAQ
• Ticker Symbol: 217330

Financial Performance

In 2023, Cytogen's revenue was 3.18 billion, an increase of 318.57% compared to the previous year's 760.78 million. Losses were -15.77 billion, -15.99% less than in 2022.